Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07408856 · ClinicalTrials.gov registry record · Phase 1
CAN1012 in Pre-Malignant DCIS and LCIS
A Phase 1 study, sponsored by Providence Health & Services.
- Not yet
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07408856 is a Phase 1 study that has not yet begun recruiting, run by Providence Health & Services. The registered enrollment target is 24 participants.
The verdict
NCT07408856, a Phase 1 study, has not yet begun recruiting, sponsored by Providence Health & Services.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a Phase I/Ib study evaluating CAN1012 in patients with ductal carcinoma in situ and lobular carcinoma in situ.
Interventions
- DRUG CAN1012
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-05 |
| Est. Completion | 2035-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07408856
The ClinicalTrials.gov registry entry for NCT07408856 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CAN1012 is the first listed.
NCT07408856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07408856 about?
NCT07408856 is a clinical study titled "CAN1012 in Pre-Malignant DCIS and LCIS". This is a Phase I/Ib study evaluating CAN1012 in patients with ductal carcinoma in situ and lobular carcinoma in situ.
What is the current status of trial NCT07408856?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-05. Estimated completion is 2035-05.
What interventions are being tested in trial NCT07408856?
The interventions under investigation include: CAN1012 (DRUG).
Who is sponsoring clinical trial NCT07408856?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.